BioXcel Therapeutics (BTAI) Other Non Operating Income (2022 - 2026)

BioXcel Therapeutics' Other Non Operating Income history runs 5 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• On a quarterly basis, Other Non Operating Income fell 76.84% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was -$8.6 million, a 132.05% decrease from a year earlier, with the FY2025 full-year figure at -$3.5 million, down 117.44% from the prior year.
• Other Non Operating Income fell to $1.5 million in Q1 2026 per BTAI's latest filing, from $1.8 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $12.0 million in Q2 2024 and bottomed at -$12.5 million in Q3 2025.
• The 5-year median for Other Non Operating Income is $537000.0 (2023), against an average of $1.2 million.
• Across the five-year window, Other Non Operating Income jumped 96440.0% in 2024 and sank 360.45% in 2025, its largest moves.
• Year by year, Other Non Operating Income stood at -$480000.0 in 2022, then soared by 122.5% to $108000.0 in 2023, then jumped by 2953.7% to $3.3 million in 2024, then sank by 45.06% to $1.8 million in 2025, then retreated by 16.17% to $1.5 million in 2026.
• Per Business Quant, the three latest BTAI Other Non Operating Income figures stand at $1.5 million (Q1 2026), $1.8 million (Q4 2025), and -$12.5 million (Q3 2025).